Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with a stable dose of metformin in combination with a stable dose of Dipeptidyl Peptidase IV (DPPIV) inhibitor and/or a Sodium-glucose co-transporter-2 (SGLT2) inhibitor for at least 3 months prior to screening~* Participants must have a HbA1c value of 7.0% to 9.5%, inclusive~* Participants must have a body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m²), inclusive~Exclusion Criteria:~* Have type 1 diabetes mellitus or latent autoimmune diabetes~* Have any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening~* Have any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)~* Have acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease~* Have an estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73 m²~* Have active or untreated cancer~* Are receiving chronic (\>14 days) systemic glucocorticoid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LY3209590 Algorithm 1 (Paper) (Type: EXPERIMENTAL): Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of \<=100 milligrams per deciliter (mg/dL).
- LY3209590 Algorithm 2 (Digital) (Type: EXPERIMENTAL): Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of \<=100 mg/dL.~As per protocol amendment (d) approved on 28-Oct-2020, this arm was terminated during the early enrollment phase due to technical issues with data entry.
- Insulin Degludec (Type: ACTIVE_COMPARATOR): Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of \<=100 mg/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete